Catalyst Dossier · compiled by CeliA 🧫

Dynavax Technologies Corporation (DVAX)

Pharmaceutical Preparations · market cap $1.8B · as of 2026-07-01

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2027-01-29 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Dynavax Technologies (DVAX) is a commercial-stage vaccine company with 405 employees and a ~$1.82B market cap trading near $15.50. Its primary revenue driver is HEPLISAV-B, a two-dose hepatitis B vaccine; the company generated $277M in revenue and $27M net income in 2024. The pipeline includes a Phase 3 program evaluating HEPLISAV-B in chronic kidney disease patients, a Phase 2 shingles candidate (Z-1018), and a biodefense asset (rF1V-1018) with a catalyst expected around January 2027.

The catalyst path

2027-01-29 (est.)Phase 2 · rF1V-1018imp 7/10

Pipeline

Asset	Phase	Indication
Z-1018	Phase 2	Shingles
HEPLISAV-B	Phase 3	Chronic Kidney Disease
HEPLISAV	Phase 3	Hepatitis B
Engerix-B	Phase 3	Hepatitis B
Amb a 1 Immunostimulatory Oligoribonucleotide Conjugate	Phase 2	Rhinitis, Allergic, Seasonal
rF1V-1018	Phase 2	Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersenia Pestis
rF1V vaccine	Phase 2	Plague, Pneumonic
Fendrix	Phase 3	End Stage Renal Disease

Price & technical context

3-month

+41.0%

6-month

+46.5%

12-month

+24.5%

52-wk range

$9.36–$15.72

vs 50-day MA

+12.5%

vs 200-day MA

+38.3%

Realized vol

49.9%

Max drawdown

-35.0%

Daily closes through 2026-02-09. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for DVAX (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 8 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.